Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Conjugate compounds

A compound and linker technology, applied in the field of glycosphingolipid analogs and their peptide derivatives, can solve the problems of lack, poor solubility, T cell anergy, etc.

Active Publication Date: 2015-10-28
VICTORIA LINK LTD
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although α-GalCer has considerable biological activity, it does have limitations, such as poor solubility (Ebensen, Link et al., 2007), lack of efficacy in human clinical trials (Giaccone, Punt et al., 2002), promoting T cell Anergy (Parekh, Wilson et al., 2005) and production of both Th1 and Th2 cytokines may cause mixed effects in model studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Conjugate compounds
  • Conjugate compounds
  • Conjugate compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0229] definition

[0230] The term "cancer" and similar terms refer to diseases or conditions in patients that are generally characterized by abnormal or unregulated cell growth. Cancer and cancer pathology can, for example, be associated with: metastasis, interference with the normal function of neighboring cells, abnormal levels of release of cytokines or other secreted products, cell proliferation, tumor formation or growth, inhibition of inflammation or immune response Or exacerbation, tumor formation, primary cancer, malignant tumor, invasion of surrounding or distant tissues or organs such as lymph nodes, etc. Specific cancers are described in detail herein. Examples include lung cancer, glioma, lymphoma, colon cancer, head and neck cancer and nasopharyngeal carcinoma (NPV), melanoma, chronic myelogenous leukemia (CML), myeloma, prostate cancer, breast cancer, glioblasts Tumor, renal cell carcinoma, liver cancer.

[0231] "Infection" and similar terms refer to a disease o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

Description

Technical field [0001] The present invention generally relates to some sphingolipid analogs and peptide derivatives thereof, a composition containing these compounds (the composition includes a pharmaceutical composition and an adjuvant composition), a method for preparing the compound, and the use thereof Methods of treating or preventing diseases or conditions with compounds, especially diseases or conditions related to cancer, infection, atopic disorders, autoimmune diseases or diabetes. Background technique [0002] Constant natural killer T cells (NKT) are a subset of T cells that are associated with various diseases. In some cases, they can enhance the response to infection (Kinjo, Illarionov et al., 2011) and cancer (Wu, Lin et al., 2011), and also inhibit autoimmune diseases (Hong, Wilson et al., 2001) and type II diabetes Ability. The activation of NKT cells can also lead to undesirable immune responses related to allergies (Wingender, Rogers et al., 2011), autoimmunit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H15/04A61P11/06A61P35/00A61K31/7028C07D309/02
CPCA61K47/48246A61K2039/55572C07D309/12C07D405/12C07D405/14C07D495/04A61K47/549A61K47/64A61P11/06A61P31/00A61P35/00A61P37/06A61P37/08A61P3/10A61K39/385A61K2039/6018A61K2039/627A61K47/646
Inventor 里根·詹姆士·安德森本杰明·杰森·康普顿科林·马尔科姆·海曼伊恩·弗朗西斯·赫尔曼斯大卫·塞缪尔·拉森加文·弗兰克·佩因特弗兰卡·龙凯赛
Owner VICTORIA LINK LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com